Free Trial

PTC Therapeutics (PTCT) Stock Price, News & Analysis

$37.20
+0.07 (+0.19%)
(As of 05/24/2024 08:50 PM ET)
Today's Range
$37.06
$38.14
50-Day Range
$24.69
$40.12
52-Week Range
$17.53
$46.76
Volume
540,500 shs
Average Volume
969,043 shs
Market Capitalization
$2.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.67

PTC Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.07 Rating Score
Upside/​Downside
4.1% Downside
$35.67 Price Target
Short Interest
Bearish
12.95% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
0.43mentions of PTC Therapeutics in the last 14 days
Based on 40 Articles This Week
Insider Trading
Selling Shares
$888,907 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.08) to ($3.70) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.19 out of 5 stars

Medical Sector

501st out of 922 stocks

Pharmaceutical Preparations Industry

223rd out of 422 stocks

PTCT stock logo

About PTC Therapeutics Stock (NASDAQ:PTCT)

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTCT Stock Price History

PTCT Stock News Headlines

PTC Therapeutics (NASDAQ:PTCT) PT Raised to $32.00
PTCT PTC Therapeutics, Inc.
See More Headlines
Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/25/2024
Today
5/27/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PTCT
Employees
988
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.67
High Stock Price Target
$55.00
Low Stock Price Target
$23.00
Potential Upside/Downside
-4.1%
Consensus Rating
Hold
Rating Score (0-4)
2.07
Research Coverage
14 Analysts

Profitability

Net Income
$-626,600,000.00
Pretax Margin
-69.62%

Debt

Sales & Book Value

Annual Sales
$937.82 million
Cash Flow
$2.42 per share
Book Value
($11.65) per share

Miscellaneous

Free Float
72,479,000
Market Cap
$2.85 billion
Optionable
Optionable
Beta
0.63
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives


PTCT Stock Analysis - Frequently Asked Questions

Should I buy or sell PTC Therapeutics stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 3 sell ratings, 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" PTCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares.
View PTCT analyst ratings
or view top-rated stocks.

What is PTC Therapeutics' stock price target for 2024?

14 Wall Street research analysts have issued 1 year target prices for PTC Therapeutics' shares. Their PTCT share price targets range from $23.00 to $55.00. On average, they predict the company's stock price to reach $35.67 in the next twelve months. This suggests that the stock has a possible downside of 4.1%.
View analysts price targets for PTCT
or view top-rated stocks among Wall Street analysts.

How have PTCT shares performed in 2024?

PTC Therapeutics' stock was trading at $27.56 at the start of the year. Since then, PTCT stock has increased by 35.0% and is now trading at $37.20.
View the best growth stocks for 2024 here
.

When is PTC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our PTCT earnings forecast
.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) released its quarterly earnings data on Thursday, April, 25th. The biopharmaceutical company reported ($1.20) EPS for the quarter, topping analysts' consensus estimates of ($1.21) by $0.01. The biopharmaceutical company had revenue of $210.12 million for the quarter, compared to the consensus estimate of $160.27 million.

What guidance has PTC Therapeutics issued on next quarter's earnings?

PTC Therapeutics issued an update on its FY 2024 earnings guidance on Thursday, April, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $600.0 million-$680.0 million, compared to the consensus revenue estimate of $606.6 million.

What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?

24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (12.22%), Janus Henderson Group PLC (4.78%), Jacobs Levy Equity Management Inc. (2.09%), Price T Rowe Associates Inc. MD (0.83%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.57%) and Assenagon Asset Management S.A. (0.40%). Insiders that own company stock include Alethia Young, Allan Steven Jacobson, Christine Marie Utter, David P Southwell, Dawn Svoronos, Emily Luisa Hill, Emma Reeve, Eric Pauwels, Jerome B Zeldis, Lee Scott Golden, Mark Elliott Boulding, Matthew B Klein, Michael Schmertzler, Neil Gregory Almstead, Pierre Gravier, Stephanie Okey and Stuart Walter Peltz.
View institutional ownership trends
.

How do I buy shares of PTC Therapeutics?

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PTCT) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners